Enable AccessibilityEnable Accessibility

Plasma-Derived Therapies

Plasma-derived therapies are critical, life-saving medicines that thousands of people with rare and complex diseases rely on every day around the world. Global demand for these therapies, particularly immunoglobulins, has increased dramatically over the last 15 years, and continues to grow.

Takeda continues to invest in building a globally respected and sustainable plasma business that will reimagine the industry to best serve patients worldwide. Our heritage, combined with our scale, expertise and capabilities, uniquely position Takeda to realize the potential of plasma-derived therapies for patients around the world.

  • Takeda has a 75+ year pioneering legacy in producing plasma-derived therapies, and is established as a top three global player with end-to-end capabilities spanning the plasma value chain from donor to patient.
  • We have a broad and differentiated portfolio of plasma-derived products, including more than 20 therapies, including a diverse offering of subcutaneous IG (SCIG) products.
  • We are a leader in rare diseases, and have a deep understanding of the patient journey.

BioLife, part of Takeda, is our global plasma collection network and an industry leader in the collection of high-quality plasma. With more than 140 centers in the U.S. and Europe, BioLife is recognized for its world-class donation safety standards and high-quality centers that deliver a positive donor experience.
Takeda is also a world leader in manufacturing plasma products at commercial scale. Our global production network comprises eight strategically located and interconnected facilities for optimal delivery of our products around the world.

Even with the scientific advances that have uncovered the value of plasma therapies to date, there remains significant untapped therapeutic potential in plasma. We are combining our expertise in rare and chronic diseases with our R&D capabilities to drive transformative patient-centric R&D with the goal of improving existing treatments and outcomes in ways that matter most to patients.